RT Journal
A1 Yang Z, Mao C, Tang J
T1 BEvacizumab and cancer treatment-related mortality
JF JAMA
JO JAMA
YR 2011
FD June 8
VO 305
IS 22
SP 2291
OP 2293
DO 10.1001/jama.2011.757
UL http://dx.doi.org/10.1001/jama.2011.757
AB 
The numbers of fatal adverse events (FAEs) were extracted incorrectly or by using different extraction criteria from some of the included studies. In the study by Hurwitz et al,2 the incidence of FAEs (“adverse event leading to death”) was 10 of 393 in the bevacizumab group and 11 of 397 in the placebo group, as opposed to 1 of 393 and 0 of 397 as reported by Ranpura et al.1 In the study by Escudier et al,3 8 of 337 in the treatment group and 7 of 304 in the control group had a “death not due to disease progression,” in contrast to 3 of 337 and 0 of 304 reported by Ranpura et al.1 In addition, the authors used the incorrect denominator for the incidence of FAEs in the study by Saltz et al4: it should be 694 in the bevacizumab group and 675 in the placebo group, instead of 675 in the treatment group and 694 in the control group, as reported in the review.1